Pathophysiology and treatment of fatigue in multiple sclerosis.

被引:10
|
作者
Boërio, D
Lefaucheur, JP
Hogrel, JY
Créange, A
机构
[1] Hop Henri Mondor, Serv Neurol, AP HP, F-94010 Creteil, France
[2] Hop Henri Mondor, Serv Physiol Explorat Fonct, AP HP, F-94010 Creteil, France
[3] Grp Hosp Pitie Salpetriere, Inst Mycol, F-75634 Paris, France
关键词
fatigue; evaluation; central and peripheral nervous system; immunology; treatment;
D O I
10.1016/S0035-3787(06)75017-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Patients suffering from multiple sclerosis (MS) frequently complain of fatigue (53 to 92 percent depending on studies). Fatigue can be one of the most disabling symptoms of MS and presents as physical or mental fatigue in daily living activities. Besides this permanent feeling of exhaustion, MS patients can suffer from an abnormal tiredness and lack of energy after a given motor or mental task, which defines fatigability. A number of studies explored the origins of fatigue and fatigability by means of subjective and objective tools. The implication of central nervous system dysfunctions has been established in several studies; however the contribution of peripheral nervous system factors and systemic abnormalities associated with inflammatory and immunological parameters was also suggested. The aim of this review is to present the different types of fatigue and fatigability occurring in MS patients, their origins, the investigation tools which allow the quantification of fatigue and fatigability and characterization of their mechanisms. The currently available therapeutic strategies that have been proposed to relieve this disabling symptom are presented.
引用
收藏
页码:311 / 320
页数:10
相关论文
共 50 条
  • [31] Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
    Cohen, JA
    Carter, JL
    Kinkel, RP
    Schwid, SR
    JOURNAL OF NEUROIMMUNOLOGY, 1999, 98 (01) : 29 - 36
  • [32] Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options - Review Article
    Zimek, Dalibor
    Miklusova, Martina
    Mares, Jan
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 2485 - 2497
  • [33] Preventive treatment of multiple sclerosis. Rules for treatment with immuno-modulators
    Izquierdo, G
    REVISTA DE NEUROLOGIA, 2002, 35 (11) : 1094 - 1099
  • [34] The issue of acute multiple sclerosis.
    Kressel, H
    ZEITSCHRIFT FUR DIE GESAMTE NEUROLOGIE UND PSYCHIATRIE, 1938, 163 (01): : 83 - 102
  • [35] Cortical demyelination in multiple sclerosis.
    Mörk, S
    Bö, L
    Trapp, B
    Nyland, H
    BRAIN PATHOLOGY, 2000, 10 (04) : 643 - 644
  • [36] The treatment of disseminated sclerosis.
    McAlpine, D
    LANCET, 1925, 2 : 82 - 83
  • [37] Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting
    Svenningsson, Anders
    Falk, Eva
    Celius, Elisabeth G.
    Fuchs, Siegrid
    Schreiber, Karen
    Berko, Sara
    Sun, Jennifer
    Penner, Iris-Katharina
    PLOS ONE, 2013, 8 (03):
  • [38] Physiopathology and treatment of fatigue in multiple sclerosis
    G. Comi
    L. Leocani
    P. Rossi
    B. Colombo
    Journal of Neurology, 2001, 248 : 174 - 179
  • [39] Physiopathology and treatment of fatigue in multiple sclerosis
    Comi, G
    Leocani, L
    Rossi, P
    Colombo, B
    JOURNAL OF NEUROLOGY, 2001, 248 (03) : 174 - 179
  • [40] Acute promyelocytic leukemia following mitoxantrone treatment of multiple sclerosis.
    Novoselac, AV
    Reddy, S
    Sanmugarajah, J
    Yudelman, I
    BLOOD, 2003, 102 (11) : 231B - 232B